Literature DB >> 6113354

Heterogeneity of prolactin responses to oestradiol benzoate in women with prolactinomas.

M C White, M Anapliotou, J Rosenstock, K Mashiter, G F Joplin.   

Abstract

Serum prolactin concentrations were measured for 72 h after intramuscular injection of 1 mg of oestradiol benzoate in six normoprolactinaemic women and nineteen with a prolactinoma (eleven with an obviously enlarged pituitary fossa and eight with a normal pituitary fossa). The group with an obvious tumour showed a rise in mean serum prolactin at 48 h to 122% of basal concentrations (p less than 0.05), and at 72 h to 137% of basal concentrations (p less than 0.01). Individual responses were variable, but in four patients serum prolactin rose to 165% or more of basal concentrations. In the group with a prolactinoma and a normal pituitary fossa serum prolactin at 72 h was 121% of basal concentrations (p less than 0.05). Normoprolactinaemic women showed no significant change in serum prolactin at any time. This study demonstrated a heterogeneity of serum prolactin responses to acute oestradiol administration in women with prolactinomas. Some patients with large tumours had a hypersensitive response to oestradiol. This heterogeneity of response could account for the present unpredictability of expansion of prolactinomas during pregnancy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6113354     DOI: 10.1016/s0140-6736(81)92571-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

Review 1.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

2.  Prolactinoma: a question of rational treatment.

Authors:  C R Edwards; C M Feek
Journal:  Br Med J (Clin Res Ed)       Date:  1981-12-12

Review 3.  Prolactinomas.

Authors:  A Grossman; G M Besser
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-19

Review 4.  PRL-secreting pituitary adenomas in pregnancy.

Authors:  I Chiodini; A Liuzzi
Journal:  J Endocrinol Invest       Date:  2003-01       Impact factor: 4.256

5.  Estrogenic treatment does not modify the TSH and PRL responses to domperidone and TRH in patients with tumoral hyperprolactinemia.

Authors:  E Ghigo; G Pogliano; C Campagnoli; A Bertagna; F Camanni; F Massara
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.